Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?
- 21 July 2006
- journal article
- clinical trial
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 21 (8), 719-721
- https://doi.org/10.1002/gps.1547
Abstract
Introduction There is little data on stopping cholinesterase inhibitors in Dementia with Lewy bodies (DLB). Equally, it is not known if increasing the dose of cholinesterase inhibitors may help neuropsychiatric symptoms in advanced DLB. Method We conducted an open label trial with donepezil involving 16 patients with LBD when the dose was reduced and treatment stopped over 4 weeks. Another 7 patients were given a trial of an increased dose of donepezil (15 mg) to resolve re‐emergent neuropsychiatric symptoms. Results The slow discontinuation protocol was well tolerated in advanced DLB. Five of the seven patients given a trial of a higher dose of donepezil were rated as clinically improved after 12 weeks treatment. Conclusion Cholinesterase inhibitors can be discontinued slowly in advanced DLB. Increasing the dose of donepezil may be of benefit to some patients with DLB who experience a recurrence in their neuropsychiatric symptoms. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 3 references indexed in Scilit:
- A comparison of the efficacy of donepezil in Parkinson's disease with Dementia and Dementia with Lewy bodiesInternational Journal of Geriatric Psychiatry, 2005
- What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementiaInternational Journal of Geriatric Psychiatry, 2003
- Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international studyThe Lancet, 2000